Basic Information
| LncRNA/CircRNA Name | PEG10 |
| Synonyms | PEG10, EDR, HB-1, MEF3L, Mar2, Mart2, RGAG3, RTL2, SIRH1 |
| Region | GRCh38_7:94656325-94669695 |
| Ensemble | ENSG00000242265 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | rituximab | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | diffuse large B-cell lymphoma |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi etc. |
| Sample | DLBCL tissues, cell lines (OCI-LY-3, OCI-LY-7, OCI-LY-10 etc.) |
| Expression Pattern | up-regulated |
| Function Description | We first found that the expression of PEG10 was upregulated in DLBCL tumorous tissues and that cell lines compared with the normal. Moreover, we illustrated that PEG10 was significantly correlated with B symptoms, IPI score, CHOP-like treatment and rituximab. |
| Pubmed ID | 25864113 |
| Year | 2015 |
| Title | Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. |
External Links
| Links for PEG10 | GenBank HGNC NONCODE |
| Links for diffuse large B-cell lymphoma | OMIM COSMIC |